NFlection Therapeutics, which is developing drug candidates for rare RASopathies, named William Hodder as CEO to replace Christopher Powala, who is retiring from day-to-day operation but will remain on the board of directors.
Photo: William Hodder, CEO of Nflection
Hodder brings more than 30 years of broad biopharmaceutical industry experience including fundraising, business development, corporate strategy, product marketing, sales, and product development to NFlection. Most recently he served as chief business officer at Escient Pharmaceuticals where he was responsible for all financing, licensing and M&A activity, and overseeing corporate operations and administrative functions while developing and implementing infrastructure to support the growth of the organization.
At NFlection, Hodder will lead efforts to discover and develop effective, targeted therapies for rare disorders known as RASopathies, initially focusing on cutaneous neurofibromas in neurofibromatosis type 1, disfiguring congenital birthmarks (including keratinocytic epidermal nevi and nevus sebaceous), and immunosuppressant-mediated squamous cell carcinoma.
The company also named Gerd Kochendoerfer, as chief operating officer, Libbie Mansell, as senior vice president of global regulatory affairs and quality assurance, and Patrice Horwath as vice president of clinical operations. Each have more than 20 years of experience in the industry.
Author: Rare Daily Staff
Stay Connected
Sign up for updates straight to your inbox.